NEW YORK, May 21, 2026, 09:11 (EDT)
Bio-Techne Corp heads into Thursday’s U.S. session with a three-day rebound behind it, after the life-science tools maker closed Wednesday at $46.70, up 2.7%. Regular Nasdaq trading had not yet opened at the dateline; Nasdaq’s main session runs from 9:30 a.m. to 4:00 p.m. Eastern, and its next listed May 2026 closure is Memorial Day on May 25.
That matters now because the rally is still a repair trade. Bio-Techne remains well below its January high after investors marked down the stock this month on weaker-than-expected fiscal third-quarter sales.
The company said on May 6 that reported and organic revenue both fell 2% to $311.4 million in the quarter ended March 31. Organic revenue, a measure that strips out currency and portfolio effects to show the underlying business, was hurt by prior-year fast-track manufacturing orders and the timing of large commercial-supply shipments, Bio-Techne said.
The broader market helped. The S&P 500 rose 1.1% on Wednesday, the Dow gained 1.3% and the Nasdaq composite advanced 1.5%, as easing Treasury yields and lower oil prices gave equities room to recover.
Bio-Techne outpaced some nearby healthcare names in the session, including Charles River Laboratories, which rose 2.4%. Even after Wednesday’s move, Bio-Techne was still about 35% below its 52-week high of $72.16, reached on Jan. 22, according to MarketWatch.
The central question is whether weak demand from emerging biotech customers is temporary or more stubborn. Reuters reported after the May 6 results that Bio-Techne missed Wall Street revenue estimates as cuts to U.S. academic funding weighed on demand for products used in drug development and medical research.
Chief Executive Kim Kelderman tried to frame the quarter as uneven, not broken. “Large pharma again led results with the sixth consecutive quarter of double-digit growth,” he said in the earnings release, adding that biotech funding “has not yet translated into broad-based demand across our portfolio.” PR Newswire
Kelderman also told analysts that the academic market had improved but was not cleanly out of trouble. “It’s still a frail market,” he said on the earnings call, adding that it was “certainly not going to be a V-shaped recovery.” Chief Financial Officer James Hippel called emerging biotech weakness “the biggest swing factor” for faster growth. The Motley Fool
One bull case sits outside the near-term revenue miss: Wilson Wolf. RBC Capital Markets analyst Dan Leonard restarted coverage with an Outperform rating, arguing Bio-Techne’s planned full acquisition of Wilson Wolf is underappreciated, Investing.com reported. Wilson Wolf makes tools used in cell therapy manufacturing; cell therapy means treatments built from living cells, often a patient’s own.
Bio-Techne already owns 20% of Wilson Wolf and has rights tied to buying the rest. The original agreement included a $257 million investment for the stake and a path to acquire the remaining ownership if Wilson Wolf hit revenue or EBITDA targets; EBITDA means earnings before interest, taxes, depreciation and amortization, a rough measure of operating cash profit.
Analysts are still leaning positive, though not without caution. MarketBeat lists Bio-Techne at a “Moderate Buy” consensus from 14 analysts, with an average 12-month price target of $65.92, above Wednesday’s close. MarketBeat
But the rebound could stall if research budgets stay tight or if biotech funding continues to flow more into later-stage clinical work than early discovery, where Bio-Techne sells many core reagents and assays. A weaker fourth quarter, another order-timing gap, or slower Wilson Wolf progress would make the recent bounce look more like short-covering than a turn in fundamentals.
